Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
← catalyst calendarNCT06712355 · readout ≤ 864 d
Sponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Bristol-Myers Squibb.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
621estimated
Sites
221
Countries
Australia, China, France +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-03 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive-stage Small-cell Lung Cancer
Interventions
- Drug: Pumitamig — also filed as BNT327, BMS-986545, PM8002
- Drug: Atezolizumab
- Drug: Etoposide
- Drug: Carboplatin (or cisplatin if carboplatin is not tolerated)
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS)
measured Up to approximately 46 months
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed